← Back to all trials
Enrolling By Invitation
NCT07734415
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 400
Sponsor: Inmagene LLC
Location: Inmagene Site 1 Lancaster California
Summary
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
Eligibility Criteria
Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203
Source: ClinicalTrials.gov (NCT07734415). StuddyBuddy aggregates publicly available trial information.
